SlideShare a Scribd company logo
1 of 10
ANTINEUTROPHIL CYTOPLASMIC ANTIBODY ASSOCIATED
VASCULITIS
Investigation show:
• Leucocytosis
• Elevated CRP, ESR,Proteinase-3(PR3)
• Diagnosis should be confirmed by biopsy of the kidney or lesion in the
sinuses and upper airway
TREATMENT :
• High dose glucocorticoids(intravenous methylprednisolone 0.5-1g for
3 days then oral prednisolone 0.5 mg/kg )
• Intravenous cyclophosphamide0.5-1g every 2 weeks for 3 month
• Followed by maintenance therapy with lower dose glucocorticoid
and azathioprine , methotrexate
• AAV has a tendency to relapse and patients must be followed on a
regular and long term basis , monitoring urinalysis for blood and
protein , plasma creatinine ,ESR,CRP, lung function and PR3 or MPO
antibody titres
TAKAYASU ARTERITIS
• Investigation show – normocytic , normochromic anaemia
• Diagnosis is based on angiography –which revels coarctation ,
occlusion and aneurysmal dilatation
• Treatment – high dose glucocorticoids and immunosuppresants
KAWASAKI DISEASE
• Treatment – aspirin 5mg/kg daily for 14 days
IVIg 400 mg/kg daily for 4 days
POLYARTERITIS NODOSA :
• Diagnosis is confirmed by magnetic resonance angiography – which
show multiple aneurysms and smooth narrowing of mesenteric ,
hepatic or renal system
• Treatment – high dose glucocorticoids and immunosuppressant
GIANT CELL ARTERITIS / POLYMYALGIA RHEUMATICA
• Investigation show :
• Elevated ESR
• Normochromic normocytic anaemia
• CRP – may be elevated
• Abnormal liver function
3 investigation to consider:
• Temporal artery biopsy
• Ultrasound of temporal arteries
• Fluorodeoxyglucose positron emission tomography (19 FDG PET scan)
Biopsy finding:
• Fragmentation of the internal elastic lamina with necrosis of media
• Inflammatory cell infiltrate
• On ultrasound :temporal artery show halo sign
Treatment :
• Prednisolone ( in GCA 60-80 mg is used but in PMR 15- 20 mg ) is
used
• In both condition, glucocorticoid dose should be progressively
reduced , guided by symptom and ESR with the aim of reaching a
dose of 10-15 mg by about 8 weeks
BEHCET’S DISEASE
• Chronic relapsing multisystem autoimmune inflammatory disease
• Target small arteries and venules
• Oral ulcer
• Genital ulcers
• Skin lesions – erythema nodosum or acneiform lesion
• Ocular involvement - anterior or posterior uveitis or retinal vasculitis
• Oral ulcer managed with topical glucocorticoid preparation ( soluble
prednisolone mouthwashes , glucocorticoid pastes )
• Colchicine can be effective for erythema nodosum and arthralgia
• Glucocorticoids and immunosuppressants are indicated for uveitis
and neurological disease
ANTINEUTROPHIL CYTOPLASMIC ANTIBODY ASSOCIATED  VASCULITIS.pptx

More Related Content

Similar to ANTINEUTROPHIL CYTOPLASMIC ANTIBODY ASSOCIATED VASCULITIS.pptx

Evaluation of proteinuria in children ppt
Evaluation of proteinuria in children pptEvaluation of proteinuria in children ppt
Evaluation of proteinuria in children ppt
Shane Watson
 
SLE: present guidelines and consensus
SLE: present guidelines and consensusSLE: present guidelines and consensus
SLE: present guidelines and consensus
Vishal Golay
 
adrenal gland hhhhhhhhhhhhhhhhhhhhhh.pdf
adrenal gland hhhhhhhhhhhhhhhhhhhhhh.pdfadrenal gland hhhhhhhhhhhhhhhhhhhhhh.pdf
adrenal gland hhhhhhhhhhhhhhhhhhhhhh.pdf
mekuriatadesse
 
uppergibleeding-150402032909-conversion-gate01.pdf
uppergibleeding-150402032909-conversion-gate01.pdfuppergibleeding-150402032909-conversion-gate01.pdf
uppergibleeding-150402032909-conversion-gate01.pdf
DakaneMaalim
 
Cushingssyndrome 160827080057
Cushingssyndrome 160827080057Cushingssyndrome 160827080057
Cushingssyndrome 160827080057
amnehmeno
 

Similar to ANTINEUTROPHIL CYTOPLASMIC ANTIBODY ASSOCIATED VASCULITIS.pptx (20)

Nephrotic syndrome
Nephrotic syndromeNephrotic syndrome
Nephrotic syndrome
 
Pulmonary vasculitis
Pulmonary vasculitisPulmonary vasculitis
Pulmonary vasculitis
 
Nephrotic syndrome, Characterized by heavy proteinuria>3.5g/m/day in adults,>...
Nephrotic syndrome, Characterized by heavy proteinuria>3.5g/m/day in adults,>...Nephrotic syndrome, Characterized by heavy proteinuria>3.5g/m/day in adults,>...
Nephrotic syndrome, Characterized by heavy proteinuria>3.5g/m/day in adults,>...
 
Physician's Meeting 23/4/2013 - Challenging Nephrotic Syndrome
Physician's Meeting 23/4/2013 - Challenging Nephrotic SyndromePhysician's Meeting 23/4/2013 - Challenging Nephrotic Syndrome
Physician's Meeting 23/4/2013 - Challenging Nephrotic Syndrome
 
Pulmonary embolism
Pulmonary embolismPulmonary embolism
Pulmonary embolism
 
Proteinuria Evaluation
Proteinuria EvaluationProteinuria Evaluation
Proteinuria Evaluation
 
Name the endocRine tumors of pancreas
Name the endocRine tumors of pancreasName the endocRine tumors of pancreas
Name the endocRine tumors of pancreas
 
Liver Transplantation
Liver Transplantation Liver Transplantation
Liver Transplantation
 
Rapidly progressive renal failure
Rapidly progressive renal failureRapidly progressive renal failure
Rapidly progressive renal failure
 
Evaluation of proteinuria in children ppt
Evaluation of proteinuria in children pptEvaluation of proteinuria in children ppt
Evaluation of proteinuria in children ppt
 
SLE: present guidelines and consensus
SLE: present guidelines and consensusSLE: present guidelines and consensus
SLE: present guidelines and consensus
 
Nephrotic Syndrome.pptx
Nephrotic Syndrome.pptxNephrotic Syndrome.pptx
Nephrotic Syndrome.pptx
 
adrenal gland hhhhhhhhhhhhhhhhhhhhhh.pdf
adrenal gland hhhhhhhhhhhhhhhhhhhhhh.pdfadrenal gland hhhhhhhhhhhhhhhhhhhhhh.pdf
adrenal gland hhhhhhhhhhhhhhhhhhhhhh.pdf
 
Nephrotic syndrome and its treatment protocols
Nephrotic syndrome and its treatment protocolsNephrotic syndrome and its treatment protocols
Nephrotic syndrome and its treatment protocols
 
Hepatorenal Syndrome.pptx
Hepatorenal Syndrome.pptxHepatorenal Syndrome.pptx
Hepatorenal Syndrome.pptx
 
Uppergibleeding 150402032909-conversion-gate01-converted
Uppergibleeding 150402032909-conversion-gate01-convertedUppergibleeding 150402032909-conversion-gate01-converted
Uppergibleeding 150402032909-conversion-gate01-converted
 
uppergibleeding-150402032909-conversion-gate01.pdf
uppergibleeding-150402032909-conversion-gate01.pdfuppergibleeding-150402032909-conversion-gate01.pdf
uppergibleeding-150402032909-conversion-gate01.pdf
 
Upper gi bleeding
Upper gi bleedingUpper gi bleeding
Upper gi bleeding
 
Cushingssyndrome 160827080057
Cushingssyndrome 160827080057Cushingssyndrome 160827080057
Cushingssyndrome 160827080057
 
Cushing's syndrome
Cushing's syndromeCushing's syndrome
Cushing's syndrome
 

More from 9459654457

investigation in pediatrics for a case of .pptx
investigation in pediatrics for a case of .pptxinvestigation in pediatrics for a case of .pptx
investigation in pediatrics for a case of .pptx
9459654457
 
hip joint anatomy physiology and injuries.pptx
hip joint anatomy physiology and injuries.pptxhip joint anatomy physiology and injuries.pptx
hip joint anatomy physiology and injuries.pptx
9459654457
 
Vasculitis- Small, medium, large vessel vasculitis.pptx
Vasculitis- Small, medium, large vessel vasculitis.pptxVasculitis- Small, medium, large vessel vasculitis.pptx
Vasculitis- Small, medium, large vessel vasculitis.pptx
9459654457
 
old-age-faculty---opmh-personality-disorders-in-older-adults-tier-2---2021394...
old-age-faculty---opmh-personality-disorders-in-older-adults-tier-2---2021394...old-age-faculty---opmh-personality-disorders-in-older-adults-tier-2---2021394...
old-age-faculty---opmh-personality-disorders-in-older-adults-tier-2---2021394...
9459654457
 

More from 9459654457 (20)

Approach to a child with hematuria- 20073.pptx
Approach to a child with hematuria- 20073.pptxApproach to a child with hematuria- 20073.pptx
Approach to a child with hematuria- 20073.pptx
 
investigation in pediatrics for a case of .pptx
investigation in pediatrics for a case of .pptxinvestigation in pediatrics for a case of .pptx
investigation in pediatrics for a case of .pptx
 
hip joint anatomy physiology and injuries.pptx
hip joint anatomy physiology and injuries.pptxhip joint anatomy physiology and injuries.pptx
hip joint anatomy physiology and injuries.pptx
 
EXPLORATORY LAPROTOMY indications and procedure.pptx
EXPLORATORY LAPROTOMY indications and procedure.pptxEXPLORATORY LAPROTOMY indications and procedure.pptx
EXPLORATORY LAPROTOMY indications and procedure.pptx
 
Vasculitis- Small, medium, large vessel vasculitis.pptx
Vasculitis- Small, medium, large vessel vasculitis.pptxVasculitis- Small, medium, large vessel vasculitis.pptx
Vasculitis- Small, medium, large vessel vasculitis.pptx
 
Lichtenstein hernioplasty surgery ppt.pptx
Lichtenstein hernioplasty surgery ppt.pptxLichtenstein hernioplasty surgery ppt.pptx
Lichtenstein hernioplasty surgery ppt.pptx
 
Steroidal contraceptives.pptx
Steroidal contraceptives.pptxSteroidal contraceptives.pptx
Steroidal contraceptives.pptx
 
old-age-faculty---opmh-personality-disorders-in-older-adults-tier-2---2021394...
old-age-faculty---opmh-personality-disorders-in-older-adults-tier-2---2021394...old-age-faculty---opmh-personality-disorders-in-older-adults-tier-2---2021394...
old-age-faculty---opmh-personality-disorders-in-older-adults-tier-2---2021394...
 
Rh negative case.pptx
Rh negative case.pptxRh negative case.pptx
Rh negative case.pptx
 
Anatomy of larynx
Anatomy of larynxAnatomy of larynx
Anatomy of larynx
 
IHD .pptx
IHD .pptxIHD .pptx
IHD .pptx
 
angina.pptx
angina.pptxangina.pptx
angina.pptx
 
CRITERIA FOR SCREENING.pptx
CRITERIA FOR SCREENING.pptxCRITERIA FOR SCREENING.pptx
CRITERIA FOR SCREENING.pptx
 
ANTENATAL_SCREENING_IN_FIRST_AND_SECOND_TRIMESTER.ppt
ANTENATAL_SCREENING_IN_FIRST_AND_SECOND_TRIMESTER.pptANTENATAL_SCREENING_IN_FIRST_AND_SECOND_TRIMESTER.ppt
ANTENATAL_SCREENING_IN_FIRST_AND_SECOND_TRIMESTER.ppt
 
Antenatal care.pptx
Antenatal care.pptxAntenatal care.pptx
Antenatal care.pptx
 
hydatid cyst.pptx
hydatid cyst.pptxhydatid cyst.pptx
hydatid cyst.pptx
 
Presentation 1.pptx
Presentation 1.pptxPresentation 1.pptx
Presentation 1.pptx
 
ca gall bladder seminar.ppt
ca gall bladder seminar.pptca gall bladder seminar.ppt
ca gall bladder seminar.ppt
 
Metabolic Alkalosis .pptx
Metabolic Alkalosis .pptxMetabolic Alkalosis .pptx
Metabolic Alkalosis .pptx
 
friends Quiz.pptx
friends Quiz.pptxfriends Quiz.pptx
friends Quiz.pptx
 

Recently uploaded

Seal of Good Local Governance (SGLG) 2024Final.pptx
Seal of Good Local Governance (SGLG) 2024Final.pptxSeal of Good Local Governance (SGLG) 2024Final.pptx
Seal of Good Local Governance (SGLG) 2024Final.pptx
negromaestrong
 
Russian Escort Service in Delhi 11k Hotel Foreigner Russian Call Girls in Delhi
Russian Escort Service in Delhi 11k Hotel Foreigner Russian Call Girls in DelhiRussian Escort Service in Delhi 11k Hotel Foreigner Russian Call Girls in Delhi
Russian Escort Service in Delhi 11k Hotel Foreigner Russian Call Girls in Delhi
kauryashika82
 
1029-Danh muc Sach Giao Khoa khoi 6.pdf
1029-Danh muc Sach Giao Khoa khoi  6.pdf1029-Danh muc Sach Giao Khoa khoi  6.pdf
1029-Danh muc Sach Giao Khoa khoi 6.pdf
QucHHunhnh
 
Beyond the EU: DORA and NIS 2 Directive's Global Impact
Beyond the EU: DORA and NIS 2 Directive's Global ImpactBeyond the EU: DORA and NIS 2 Directive's Global Impact
Beyond the EU: DORA and NIS 2 Directive's Global Impact
PECB
 
Making and Justifying Mathematical Decisions.pdf
Making and Justifying Mathematical Decisions.pdfMaking and Justifying Mathematical Decisions.pdf
Making and Justifying Mathematical Decisions.pdf
Chris Hunter
 

Recently uploaded (20)

Unit-V; Pricing (Pharma Marketing Management).pptx
Unit-V; Pricing (Pharma Marketing Management).pptxUnit-V; Pricing (Pharma Marketing Management).pptx
Unit-V; Pricing (Pharma Marketing Management).pptx
 
Food Chain and Food Web (Ecosystem) EVS, B. Pharmacy 1st Year, Sem-II
Food Chain and Food Web (Ecosystem) EVS, B. Pharmacy 1st Year, Sem-IIFood Chain and Food Web (Ecosystem) EVS, B. Pharmacy 1st Year, Sem-II
Food Chain and Food Web (Ecosystem) EVS, B. Pharmacy 1st Year, Sem-II
 
Seal of Good Local Governance (SGLG) 2024Final.pptx
Seal of Good Local Governance (SGLG) 2024Final.pptxSeal of Good Local Governance (SGLG) 2024Final.pptx
Seal of Good Local Governance (SGLG) 2024Final.pptx
 
Basic Civil Engineering first year Notes- Chapter 4 Building.pptx
Basic Civil Engineering first year Notes- Chapter 4 Building.pptxBasic Civil Engineering first year Notes- Chapter 4 Building.pptx
Basic Civil Engineering first year Notes- Chapter 4 Building.pptx
 
Russian Escort Service in Delhi 11k Hotel Foreigner Russian Call Girls in Delhi
Russian Escort Service in Delhi 11k Hotel Foreigner Russian Call Girls in DelhiRussian Escort Service in Delhi 11k Hotel Foreigner Russian Call Girls in Delhi
Russian Escort Service in Delhi 11k Hotel Foreigner Russian Call Girls in Delhi
 
1029-Danh muc Sach Giao Khoa khoi 6.pdf
1029-Danh muc Sach Giao Khoa khoi  6.pdf1029-Danh muc Sach Giao Khoa khoi  6.pdf
1029-Danh muc Sach Giao Khoa khoi 6.pdf
 
Unit-IV; Professional Sales Representative (PSR).pptx
Unit-IV; Professional Sales Representative (PSR).pptxUnit-IV; Professional Sales Representative (PSR).pptx
Unit-IV; Professional Sales Representative (PSR).pptx
 
Energy Resources. ( B. Pharmacy, 1st Year, Sem-II) Natural Resources
Energy Resources. ( B. Pharmacy, 1st Year, Sem-II) Natural ResourcesEnergy Resources. ( B. Pharmacy, 1st Year, Sem-II) Natural Resources
Energy Resources. ( B. Pharmacy, 1st Year, Sem-II) Natural Resources
 
INDIA QUIZ 2024 RLAC DELHI UNIVERSITY.pptx
INDIA QUIZ 2024 RLAC DELHI UNIVERSITY.pptxINDIA QUIZ 2024 RLAC DELHI UNIVERSITY.pptx
INDIA QUIZ 2024 RLAC DELHI UNIVERSITY.pptx
 
Holdier Curriculum Vitae (April 2024).pdf
Holdier Curriculum Vitae (April 2024).pdfHoldier Curriculum Vitae (April 2024).pdf
Holdier Curriculum Vitae (April 2024).pdf
 
Introduction to Nonprofit Accounting: The Basics
Introduction to Nonprofit Accounting: The BasicsIntroduction to Nonprofit Accounting: The Basics
Introduction to Nonprofit Accounting: The Basics
 
Advanced Views - Calendar View in Odoo 17
Advanced Views - Calendar View in Odoo 17Advanced Views - Calendar View in Odoo 17
Advanced Views - Calendar View in Odoo 17
 
Unit-IV- Pharma. Marketing Channels.pptx
Unit-IV- Pharma. Marketing Channels.pptxUnit-IV- Pharma. Marketing Channels.pptx
Unit-IV- Pharma. Marketing Channels.pptx
 
Application orientated numerical on hev.ppt
Application orientated numerical on hev.pptApplication orientated numerical on hev.ppt
Application orientated numerical on hev.ppt
 
Beyond the EU: DORA and NIS 2 Directive's Global Impact
Beyond the EU: DORA and NIS 2 Directive's Global ImpactBeyond the EU: DORA and NIS 2 Directive's Global Impact
Beyond the EU: DORA and NIS 2 Directive's Global Impact
 
Making and Justifying Mathematical Decisions.pdf
Making and Justifying Mathematical Decisions.pdfMaking and Justifying Mathematical Decisions.pdf
Making and Justifying Mathematical Decisions.pdf
 
Key note speaker Neum_Admir Softic_ENG.pdf
Key note speaker Neum_Admir Softic_ENG.pdfKey note speaker Neum_Admir Softic_ENG.pdf
Key note speaker Neum_Admir Softic_ENG.pdf
 
ICT role in 21st century education and it's challenges.
ICT role in 21st century education and it's challenges.ICT role in 21st century education and it's challenges.
ICT role in 21st century education and it's challenges.
 
ComPTIA Overview | Comptia Security+ Book SY0-701
ComPTIA Overview | Comptia Security+ Book SY0-701ComPTIA Overview | Comptia Security+ Book SY0-701
ComPTIA Overview | Comptia Security+ Book SY0-701
 
Asian American Pacific Islander Month DDSD 2024.pptx
Asian American Pacific Islander Month DDSD 2024.pptxAsian American Pacific Islander Month DDSD 2024.pptx
Asian American Pacific Islander Month DDSD 2024.pptx
 

ANTINEUTROPHIL CYTOPLASMIC ANTIBODY ASSOCIATED VASCULITIS.pptx

  • 1. ANTINEUTROPHIL CYTOPLASMIC ANTIBODY ASSOCIATED VASCULITIS Investigation show: • Leucocytosis • Elevated CRP, ESR,Proteinase-3(PR3) • Diagnosis should be confirmed by biopsy of the kidney or lesion in the sinuses and upper airway TREATMENT : • High dose glucocorticoids(intravenous methylprednisolone 0.5-1g for 3 days then oral prednisolone 0.5 mg/kg ) • Intravenous cyclophosphamide0.5-1g every 2 weeks for 3 month
  • 2. • Followed by maintenance therapy with lower dose glucocorticoid and azathioprine , methotrexate • AAV has a tendency to relapse and patients must be followed on a regular and long term basis , monitoring urinalysis for blood and protein , plasma creatinine ,ESR,CRP, lung function and PR3 or MPO antibody titres
  • 3. TAKAYASU ARTERITIS • Investigation show – normocytic , normochromic anaemia • Diagnosis is based on angiography –which revels coarctation , occlusion and aneurysmal dilatation • Treatment – high dose glucocorticoids and immunosuppresants
  • 4. KAWASAKI DISEASE • Treatment – aspirin 5mg/kg daily for 14 days IVIg 400 mg/kg daily for 4 days POLYARTERITIS NODOSA : • Diagnosis is confirmed by magnetic resonance angiography – which show multiple aneurysms and smooth narrowing of mesenteric , hepatic or renal system • Treatment – high dose glucocorticoids and immunosuppressant
  • 5. GIANT CELL ARTERITIS / POLYMYALGIA RHEUMATICA • Investigation show : • Elevated ESR • Normochromic normocytic anaemia • CRP – may be elevated • Abnormal liver function 3 investigation to consider: • Temporal artery biopsy • Ultrasound of temporal arteries • Fluorodeoxyglucose positron emission tomography (19 FDG PET scan)
  • 6. Biopsy finding: • Fragmentation of the internal elastic lamina with necrosis of media • Inflammatory cell infiltrate • On ultrasound :temporal artery show halo sign Treatment : • Prednisolone ( in GCA 60-80 mg is used but in PMR 15- 20 mg ) is used • In both condition, glucocorticoid dose should be progressively reduced , guided by symptom and ESR with the aim of reaching a dose of 10-15 mg by about 8 weeks
  • 7. BEHCET’S DISEASE • Chronic relapsing multisystem autoimmune inflammatory disease • Target small arteries and venules • Oral ulcer • Genital ulcers • Skin lesions – erythema nodosum or acneiform lesion • Ocular involvement - anterior or posterior uveitis or retinal vasculitis
  • 8.
  • 9. • Oral ulcer managed with topical glucocorticoid preparation ( soluble prednisolone mouthwashes , glucocorticoid pastes ) • Colchicine can be effective for erythema nodosum and arthralgia • Glucocorticoids and immunosuppressants are indicated for uveitis and neurological disease